Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
Creative Medical Technology Holdings (NASDAQ: CELZ) filed a new U.S. provisional patent application to broaden intellectual property protection around Ultrasome, its proprietary cell-free regenerative medicine platform. The filing seeks coverage across product composition, biological potency, manufacturing and quality control, stability, delivery methods and therapeutic applications, and builds on an April 2026 pilot study in which approximately 93% of knee osteoarthritis participants showed clinically meaningful improvement with no serious adverse events.
Key figures
- Filing type
- U.S. provisional patent application
- Pilot indication
- knee osteoarthritis
- Pilot responder rate
- approximately 93%
- Pilot serious adverse events
- none reported
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.